NCT05125471View on ClinicalTrials.gov

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

September 3, 2025

Study Completion Date

September 3, 2025

Conditions
Arteriovenous Malformations (Extracranial)
Interventions
DRUG

Cobimetinib

Adult dosing (\>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (\<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).

Trial Locations (1)

72202

Arkansas Children's Hospital, Little Rock

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Arkansas

OTHER

NCT05125471 - Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study) | Biotech Hunter | Biotech Hunter